duchenne Ireland - Collaboration

By: Duchenne Ireland  05/12/2011
Keywords: therapies

Duchenne Ireland announced today, the completion of the first stage of their Personalized Exon Skipping research project.

Skin biopsy samples were collected atthe Central Remedial Clinic in Dublin on July 8th 2011 and transported to the Newcastle BIO Bank in the UK where they await cell culture procedures before transport to Professor Steve Wilton’s laboratory in the University of Western Australia.

Speaking about the research project, Dr. Bryan Lynch Paediatric Neurologist at Temple Street Children's Hospital and the CRC said: "The goodwill and enthusiasm of all associated with this project is incalculable".

Thanks must be given to all of Duchenne Ireland’s supporters for their efforts with fundraising which has allowed Duchenne Ireland to fund this international project in its entirety. We would also like to thank the Duchenne Ireland research committee for the efforts to bring the project to its current stage.

Special thanks to the clinicians, nurses, patients and families who participated in the collection of the samples on the day and the great support families received during recruitment for the project. We acknowledge the pivotal role played by Professor Kay Ohlendiek and his team from NUI Maynooth who continue to liase between all participants in the project. Appreciation must also be shown for Professor Hanns Lochmüller and Professor Katie Bushby from Newcastle University for their collaboration on sample storage and cell culture at the Newcastle BioBank and final shipment to Professor Wilton's laboratory in Australia.

Finally, this project would not be in place at all if it was not for the dedicated work of Professor Steve Wilton and Professor Sue Fletcher from the University of Western Australia who have consistently progressed therapies for Duchenne boys over the past number of years since Exon Skipping showed initial therapeutic potential.

 

Pictured in the photograph at the CRC on the 8th of July were: (left to right): Dr. Bryan Lynch, Steve Carbery, Eoin O Rathaillaigh, SuzanneKeily, Margaret Goode, Therese Nestor, Aoife Carey.

Description of the research project onExon Skipping Therapy

This research project funded entirely by Duchenne Ireland's supporters is based onlocating the exon that is faulty in specific patient samples and willthen screen for the genetic drug which is most likely to block the defective process in this dystrophic sample. Since the human DMD gene contains 79 different exons, many different types of anti-sense molecules have to be tested. This fact makes this research project very complex. Following the skin biopsy procedure, the tissue sample will be transferred to a container with a biological liquid rich in nutrients. The potential contamination of the tissue sample with infectious agents, such as bacteria, will be prevented and controlled with antibiotics. This is important for the subsequent step of cell culturing.

Individual cells will then be produced from patient tissue samples. Cells will be stored in a BioBank Facility and samples shipped to the laboratory of Prof. Steve Wilton for genetic analysis. Cell samples will be exclusively used for this exon skipping project. At the end of the project, tissue samples will be destroyed or kept as a reference in the BioBank Facility if this is the wish of the participating patient. Tissue samples will be transferred anonymously and only suitable medical information, that might be helpful for the genetic study, will be supplied to the research laboratory.

Keywords: therapies

Contact Duchenne Ireland

Email

Print this page

Share

Other products and services from Duchenne Ireland

05/12/2011

duchenne Ireland - News

Three patients, one each in the 2.0, 10 and 20 mg/kg cohorts, demonstrated substantial generation of new dystrophin-positive muscle fibers, including the first ever reported generation of dystrophin-positive muscle fibers of more than 50% of normal in a patient following systemic administration of a drug.


05/12/2011

duchenne Ireland - Research

Safety study follow-on clinical study for patients who participated in earlier ataluren. If you have any questions relating to this announcement or the follow-on safety study. As reported in our June Programme Update, Genzyme has been actively exploring. Ataluren and as part of our ongoing commitment in keeping the DBMD community. Transition of all DBMD related activities to PTC. PTC for the ataluren nmDBMD programme.


05/12/2011

duchenne Ireland - Events

The cycle arranged to fund research into Duchenne Muscular Dystrophy will take the participants from the National University of Ireland in Galway to Maynooth. Cyclists accross Ireland are getting ready for the inaugural "Tour Duchenne" charity cycling event on Saturday 12th and Sunday 13th of September 2009. Be on the look out for our yellow "Tour Duchenne 2009" cycling jerseys.


05/12/2011

duchenne Ireland - Fundraising

Funding for Duchenne Ireland research is generated from charity events such as this weekend’s Tour Duchenne 2010, taking place at 9am at the Aquarium, Strand Road, Bray.Tour Duchenne Is Duchenne Ireland’s annual charity cycle to raise funds for Duchenne Muscular Dystrophy research.